Company intelligence / Profile preview

Suzhou Junjing BioSciences

Suzhou, Jiangsu, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Suzhou Junjing BioSciences is an innovative biotechnology joint venture focused on developing small molecule therapeutics targeting critical unmet needs in oncology. Its lead assets are in early clinical development (Phase 1/2), with a focus on advanced solid tumors and EGFR-mutant non-small cell lung cancer. The company has received IND approvals from both Chinese and US regulators for its XPO1 inhibitor program.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

js111

2 more assets in the full pipeline.

Request access →

Partnerships

Junshi BiosciencesMicroecology BiosciencesWigen Biomedicine Technology (for specific programs)Academic collaborations mentioned but not detailed

Beyond the preview

Go deeper on Suzhou Junjing BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Junjing BioSciences.

Explore the full profile